Fig. 1From: Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world studyKaplan–Meier plots of median A progression-free survival (PFS), B time-to-progression (TTP), and C overall survival (OS) in patients treated with TACE plus regorafenibBack to article page